Valuation : OLIPASS Corporation

Market Cap 26.53B 19.79M 17.05M 16.15M 14.64M 27.46M 1.89B 27.6M 192M 73.75M 962M 74.33M 72.7M 3.04B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 15.17M 13.07M 12.38M 11.22M 21.05M 1.45B 21.15M 147M 56.53M 737M 56.98M 55.73M 2.33B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
130,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 2025-05-21
Corporate Officer/Principal 34 2024-11-27
Comptroller/Controller/Auditor 67 2025-03-30
Director TitleAgeSince
Director/Board Member 54 2024-11-27
Director/Board Member 34 2024-11-27
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-93.58% 10.05M
-2.11%-1.68%+44.52%+95.15% 66.93B
-0.23%-4.45%+30.39%+73.64% 61.97B
+1.67%+2.47%-11.23%+388.34% 28.27B
-1.05%-4.43%+30.56%+10.07% 24.59B
+0.34%-6.78%-7.27%-17.99% 24.3B
+0.43%-3.37%+14.85%-19.29% 19.41B
-3.03%-2.29%+185.12%+334.07% 16.77B
-1.94%-4.94%-5.29%+495.65% 14.18B
-2.28%-4.90%+43.64%+155.21% 13.91B
Average -2.21%-7.70%+32.53%+142.13% 27.03B
Weighted average by Cap. -0.84%-3.06%+33.46%+133.66%

Financials

2021 2022
Net sales 852M 635K 547K 518K 470K 882K 60.71M 886K 6.16M 2.37M 30.89M 2.39M 2.33M 97.59M 2.3B 1.71M 1.48M 1.4M 1.27M 2.38M 164M 2.39M 16.6M 6.38M 83.25M 6.43M 6.29M 263M
Net income -25.13B -18.75M -16.16M -15.3M -13.87M -26.01M -1.79B -26.14M -182M -69.87M -911M -70.42M -68.88M -2.88B -24.17B -18.03M -15.53M -14.71M -13.33M -25.01M -1.72B -25.14M -175M -67.18M -876M -67.71M -66.23M -2.77B
Net Debt -18.29B -13.65M -11.76M -11.13M -10.09M -18.93M -1.3B -19.03M -132M -50.84M -663M -51.25M -50.12M -2.1B -6.2B -4.62M -3.98M -3.77M -3.42M -6.41M -442M -6.44M -44.78M -17.22M -225M -17.36M -16.98M -710M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!